Oncology Cancer Drugs Market Report 2024 (Global Edition)

Global Oncology Cancer Drugs Market Report 2024 Market Size Split by Drug Class (Cytotoxic Drugs, Alkylating Agents, Antimetabolites, Others, Targeted Drugs, Monoclonal Antibodies, Others, Hormonal Dr...

Oncology Cancer Drugs Market Report Description

We have various report editions of Oncology Cancer Drugs Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Oncology Cancer Drugs Market Insights Video

Competitive Landscape of the Oncology Cancer Drugs Market

The competitive landscape of the Oncology Cancer Drugs market is characterized by intense rivalry among key players, including pharmaceutical giants. The companies are investing heavily in R&D to develop innovative therapies, including targeted drugs and immunotherapies. Collaborations, mergers, and acquisitions are common strategies to expand product portfolios and market reach. The market is also witnessing the entry of biotechnology firms and startups, adding to the competition. Patent expirations and the introduction of biosimilars are further intensifying competition, leading to pricing pressures and the need for continuous innovation.

In January 2023, Reblozyl® (luspatercept) for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent: Bristol Myers Squibb Receives Positive CHMP Opinion (NTD) Thalassemia beta (Source: https://news.bms.com/news/corporate-financial/2020/Reblozyl-luspatercept-Receives-Positive-CHMP-Opinion-for-the-Treatment-of-Adults-with-Anemia-in-Beta-Thalassemia-and-Myelodysplastic-Syndromes/default.aspx) In February 2023, Roche released encouraging results from its global phase III program for treating PNH, a rare but serious blood disorder (Source: https://thalassaemia.org.cy/news/clinical-results-roche-reports-positive-data-for-crovalimab-as-rare-blood-disease-treatment/

Top Companies Market Share in Oncology Cancer Drugs Industry: (In no particular order of Rank)

• AbbVie Inc.
• Amgen
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Hoffmann-La Roche Ltd.
• Johnson & Johnson (Janssen Global Services
• LLC)
• Merck & Co.
• Inc.
• Novartis AG
• Pfizer Inc.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Oncology Cancer Drugs Market

Which Region Dominates the Oncology Cancer Drugs Market in 2024?

According to Cognitive Market Research, North America dominated the market in 2024. It accounted for around 40% of the global revenue due to several factors, including the high Prevalence of various cancer types, advanced healthcare infrastructure, and significant investment in research and development. The region's well-established pharmaceutical companies, coupled with strong regulatory frameworks, support the swift approval and commercialization of oncology drugs.

Which Region is Expanding at the Fastest CAGR?

Asia Pacific stands out as the fastest-growing region in the Oncology Cancer Drugs market due to rising cancer incidence, improving healthcare infrastructure, and growing awareness about early diagnosis and treatment. Economic growth in countries like China and India has led to increased healthcare spending, making cancer treatments more accessible. Additionally, government initiatives to improve cancer care and the rising adoption of novel therapies are propelling market expansion. The region's large patient pool and increasing clinical trials are attracting global pharmaceutical companies, further boosting market growth.

The current report Scope analyzes Oncology Cancer Drugs Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Oncology Cancer Drugs Market

According to Cognitive Market Research, the global Oncology Cancer market size was estimated at USD 169548.2 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 67819.28 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Oncology Cancer Drugs market with a market size of USD 53509.41 million in 2024 and is projected to grow at a CAGR of 6.0% during the forecast period. The nation's advanced healthcare infrastructure and research.
• The Canada Oncology Cancer Drugs Market had a market share of USD 8138.31 million in 2024 and is projected to grow at a CAGR of 7.0% during the forecast period. Canada's increasing investments in cancer research and treatment advancements.
• The Mexico Oncology Cancer Drugs Market is projected to witness growth at a CAGR of 6.7% during the forecast period, with a market size of USD 6171.55 million in 2024.

Europe Oncology Cancer Drugs Market

According to Cognitive Market Research, the global Oncology Cancer market size was estimated at USD 169548.2 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 50864.46 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.5%from 2024 to 2031.

• The United Kingdom Oncology Cancer Drugs Market had a market share of USD 8545.23 million in 2024 and is projected to grow at a CAGR of 7.3% during the forecast period. In the UK, Oncology Cancer Drug sales witness an upswing due to its advanced healthcare system and research capabilities.
• The France Oncology Cancer Drugs market is projected to witness growth at a CAGR of 5.7% during the forecast period, with a market size of USD 4679.53 million in 2024.
• According to Cognitive Market Research, the German Oncology Cancer Drugs market size was valued at USD 10071.16 million in 2024 and is projected to grow at a CAGR of 6.7% during the forecast period. In Germany, increasing investment in innovative cancer treatments and a robust pharmaceutical sector.
• The Italy Oncology Cancer Drugs Market is projected to witness growth at a CAGR of 5.9% during the forecast period, with a market size of USD 4374.34 million in 2024.
• The Russia Oncology Cancer Drugs Market is projected to witness growth at a CAGR of 5.5% during the forecast period, with a market size of USD 7883.99 million in 2024.
• The Spain Oncology Cancer Drugs market is projected to witness growth at a CAGR of 5.6% during the forecast period with a market size of USD 4170.89 million in 2024
• The LuxembourgOncology Cancer Drugs Market is projected to witness growth at a CAGR of 6.6% during the forecast period, with a market size of USD 1576.80 million in 2024.
• The PortugalOncology Cancer Drugs market is projected to witness growth at a CAGR of 6.3% during the forecast period, with a market size of USD 1068.15 million in 2024.
• The GreeceOncology Cancer Drugs market is projected to witness growth at a CAGR of 6.8%during the forecast period, with a market size of USD 610.37 million in 2024.
• Rest of Europe'sOncology Cancer drugs market is projected to witness growth at a CAGR of 5.2% during the forecast period, with a market size of USD 7883.99 million in 2024.

Asia Pacific Oncology Cancer Drugs Market

According to Cognitive Market Research, the global Oncology Cancer market size was estimated at USD 169548.2 Million, out of which Asia Pacific held the market share ofaround23% of the global revenue with a market size of USD 38996.09 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.0% from 2024 to 2031.

• According to Cognitive Market Research, the China Oncology Cancer Drugs Market size was valued at USD 17548.24 million in 2024 and is projected to grow at a CAGR of 9.5% during the forecast period. Oncology cancer drugs are being surged in China due to its large patient population and advanced healthcare infrastructure.
• The Japan Oncology Cancer Drugs Market is projected to witness growth at a CAGR of 8.5% during the forecast period, with a market size of USD 5381.46 million in 2024.
• The India Oncology Cancer Drugs Market had a market share of USD 4679.53 million in 2024 and is projected to grow at a CAGR of 11.8% during the forecast period. India's increasing cancer incidences and expanding access to innovative treatments.
• The South Korean Oncology Cancer Drugs Market is projected to witness growth at a CAGR of 9.1% during the forecast period, with a market size of USD 3899.61 million in 2024.
• The Australian Oncology Cancer Drugs Market is projected to witness growth at a CAGR of 9.7% during the forecast period, with a market size of USD 2027.80 million in 2024.
• The South East Asia Oncology Cancer Drugs Market is projected to witness growth at a CAGR of 11.0% during the forecast period, with a market size of USD 2690.73 million in 2024.
• The Rest of the Asia Pacific Oncology Cancer Drugs market is projected to witness growth at a CAGR of 9.8% during the forecast period, with a market size of USD 2768.72 million in 2024.

South America Oncology Cancer Drugs Market

According to Cognitive Market Research, the global Oncology Cancer market size was estimated at USD 169548.2 Million, out of which Latin America held the market share of around 5% of the global revenue with a market size of USD 8477.41 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.4%from 2024 to 2031..

• According to Cognitive Market Research, the Brazil Oncology Cancer Drugs market size was valued at USD 3628.33 million in 2024 and is projected to grow at a CAGR of 8.0% during the forecast period. Oncology Cancer drugs flourished in Brazil due to its large patient population and healthcare infrastructure.
• Argentina's Oncology Cancer Drugs Market had a market share of USD 1424.20 million in 2024 and is projected to grow at a CAGR of 8.3% during the forecast period. Argentina's increasing investment in healthcare and rising cancer incidence rates.
• Colombia's Oncology Cancer Drugs market is projected to witness growth at a CAGR of 7.2% during the forecast period, with a market size of USD 754.49 million in 2024.
• Peru Oncology Cancer Drugs Market is projected to witness growth at a CAGR of 7.6% during the forecast period, with a market size of USD 695.15 million in 2024.
• Chile Oncology Cancer Drugs Market is projected to witness growth at a CAGR of 7.7% during the forecast period, with a market size of USD 610.37 million in 2024.
• The Rest of Latin America's Oncology Cancer drugs market is projected to witness growth at a CAGR of 6.5% during the forecast period, with a market size of USD 1364.86 million in 2024.

Middle East and Africa Oncology Cancer Drugs Market

According to Cognitive Market Research, the global Oncology Cancer market size was estimated at USD 169548.2 Million, out of which the Middle East and Africa held the major market share of 2% of the global revenue with a market size of USD 3390.96 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.7%from 2024 to 2031..

• The GCC Countries Oncology Cancer Drugs Market is projected to witness growth at a CAGR of 8.5% during the forecast period, with a market size of USD 1451.33 million in 2024. Oncology Cancer Drug sales flourish due to robust healthcare infrastructure and investment.
• The Egypt Oncology Cancer Drugs Market is projected to witness growth at a CAGR of 8.0% during the forecast period, with a market size of USD 356.05 million in 2024.
• The South Africa Oncology Cancer Drugs Market is projected to witness growth at a CAGR of 8.7% during the forecast period, with a market size of USD 535.77 million in 2024. Oncology Cancer Drug sales flourish in South Africa due to increasing cancer incidence and improvements in healthcare access and treatments.
• The Turkey Oncology Cancer Drugs Market is projected to witness growth at a CAGR of 7.2% during the forecast period, with a market size of USD 291.62 million in 2024.
• The Nigeria Oncology Cancer Drugs Market is projected to witness growth at a CAGR of 6.8% during the forecast period, with a market size of USD 356.05 million in 2024.
• The Rest of the MEA Oncology Cancer Drugs market is projected to witness growth at a CAGR of 6.7% during the forecast period, with a market size of USD 400.13 million in 2024.

Oncology Cancer Drugs Market Analysis

Oncology Cancer Drugs Market Drug Class Segment Analysis

According to Cognitive Market Research, Cytotoxic Drugs stand out as the dominant category over the projected period due to their established role in treating a wide range of cancers. These drugs, which include agents like cyclophosphamide and doxorubicin, work by killing or inhibiting the growth of cancer cells through their cytotoxic effects. Their long history of use and significant impact on various cancer types contribute to their leading position in the market.

Targeted Drugs emerge as the fastest-growing category in the Oncology Cancer Drugs Market. Targeted therapies are designed to specifically attack cancer cells by targeting molecular markers or pathways critical for cancer cell survival and proliferation. This precision reduces damage to healthy cells and often results in fewer side effects.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Oncology Cancer Drugs Industry. Request a Free Sample PDF!

Oncology Cancer Drugs Market Therapy Segment Analysis

According to Cognitive Market Research, the dominant category is Chemotherapy due to its broad application in treating various types of cancers. This approach uses powerful drugs to target rapidly dividing cancer cells, and its effectiveness in managing and reducing tumors has cemented its position as a cornerstone of cancer treatment.

The fastest-growing category in the Oncology Cancer Drugs market is Targeted Therapy sports due to specific molecular targets associated with cancer cells, sparing normal cells and thereby reducing side effects compared to traditional Chemotherapy. The rapid advancement in understanding cancer genomics and molecular biology has significantly enhanced the development of targeted therapies.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Oncology Cancer Drugs Indication Segment Analysis

Oncology Cancer Drugs Market Indication Segment Analysis

According to Cognitive Market Research, the dominant category is Lung Cancer due to its high Prevalence and significant mortality rates worldwide. Lung cancer's dominance in the market is driven by its high incidence, extensive research funding, and ongoing development of targeted therapies and immunotherapies.

The fastest-growing category in the Oncology Cancer Drugs market is Stomach Cancer due to increasing awareness and diagnostic improvements. Stomach cancer's rapid growth is attributed to rising incidences in regions such as East Asia, where dietary factors and infection rates contribute to higher cancer rates. Advances in treatment options, including novel targeted therapies and combination regimens, are driving the growth in this segment.

• Lung Cancer
• Stomach Cancer
• Colorectal Cancer
• Breast Cancer
• Prostate Cancer
• Liver Cancer
• Esophagus Cancer
• Cervical Cancer
• Kidney Cancer
• Bladder Cancer
• Others

Author's Detail

David Fuller

Senior Analyst at Cognitive Market Research

LinkedIn

Profile

I am working as a Senior Analyst with Cognitive Market Research in the areas of Industry Survey and Market Research/Analytics. I collaborate with CXOs, VPs, and other senior executives to understand their data needs and provide solutions and business strategy building.

Author's Conclusion